Business Context and Reporting Period
This Form 8-K Current Report is filed by Hancock Jaffe Laboratories, Inc. (not Envveno Medical Corp as indicated in metadata) for the period ending October 2, 2018. The report details significant changes to the Company's Board of Directors, including the resignation of three directors and the appointment of three new directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Resignations: On October 1, 2018, Robert Doyle, Steven Girgenti, and Robert Andersen resigned from the Board of Directors and all associated committees.
- Compensation for Resigning Directors: Each resigning director received a grant of 10,000 options to purchase common stock at the closing price on October 1, 2018, exercisable for 10 years.
- New Appointments: On October 2, 2018, the Board appointed Dr. Francis Duhay, Dr. Sanjay Shrivastava, and Marc W. Robins, CFA, to fill the vacancies.
- Committee Assignments:
- Marc W. Robins: Chairman of the Audit Committee.
- Dr. Sanjay Shrivastava: Chairman of the Compensation Committee.
- Dr. Francis Duhay: Chairman of the Nominating and Corporate Governance Committee.
- Board Composition: The Board now consists of five members, with three classified as independent directors.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. No specific risks or contingencies related to the resignations or appointments were disclosed beyond standard contractual provisions (confidentiality, non-disparagement, and mutual releases). The Company stated there are no material plans or contracts involving the new directors that are reportable under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the exact strike price of the 10,000 options granted to each resigning director based on the October 1, 2018 closing price.
- Review the full text of the Resignation Agreements (Exhibit 10.1) for any non-standard terms.
- Confirm the independence status of the new directors and their specific qualifications relative to the Company's medical device focus.
- Check for any subsequent filings regarding the transition of leadership or strategic direction following the board overhaul.